Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings

BJU International

Volumn 101, Issue 1, 2008, Pages 26-29

  Bergman, Jonathan ^a,c   Reznichek, Richard C ^a,b   Rajfer, Jacob ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Bladder cancer; Bladder washing; Cytology; FISH; UroVysion

Indexed keywords

ADULT; AGED; ARTICLE; ASSAY; BLADDER BIOPSY; BLADDER CARCINOMA; BLADDER IRRIGATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CHI SQUARE TEST; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTOSCOPY; CYTOLOGY; DIAGNOSTIC IMAGING; DISEASE MARKER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; INFORMATION PROCESSING; MALE; MEDICAL RECORD REVIEW; PREDICTION AND FORECASTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; URINE CYTOLOGY;

ADULT; AGED; BIOPSY; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; URINARY BLADDER; URINARY BLADDER NEOPLASMS; URINE;

EID: 36848999368     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07183.x     Document Type: Article

References (30)

1. Rodgers M, Nixon J, Hempel S et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess 2006 10 : 3 259
2. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005 47 : 736 48
3. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003 169 : 1975 82
4. Solsona E, Iborra I, Rubio J, Casanova J, Dumont R, Monros JL. Late oncological occurrences following radical cystectomy in patients with bladder cancer. Eur Urol 2003 43 : 489 94
5. Kenworthy P, Tanguay S, Dinney CP. The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter. J Urol 1996 155 : 501 3
6. Reznikoff CA, Sarkar S, Juelicher P et al. Genetic alterations and biological pathways in human bladder cancer. Urol Oncol 2000 5 : 191 203
7. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J et al. Prognostic factors in stage T1 grade 3 bladder cancer survival. the role of G1-S modulators (p53, 21Waf1, 27kip1, cyclin D1 and cyclin D3) and proliferation index (ki67-Mib1). Eur Urol 2004 45 : 606 12
8. Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer: progression and recurrence. J Urol 1983 130 : 142 7
9. Mhawech P, Greloz V, Oppikofer C, Szalay-Quinodoz I, Herrmann F. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer 2004 100 : 2367 75
10. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003 61 : 109 18
11. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol 2001 165 : 600 11
12. Han M, Schoenberg MP. The use of molecular diagnostics in bladder cancer. Urol Oncol 2000 5 : 87 92
13. Ross JS, Cohen MB. Ancillary methods for the detection of recurrent urothelial neoplasia. Cancer Cytopathol 2000 90 : 75 86
14. Dey P. Urinary markers of bladder carcinoma. Clin Chem Acta 2004 340 : 57 65
15. Golijanin D, Shapiro A, Pode D. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer. J Urol 2000 164 : 1922 5
16. Sanchez-Carbayo M, Urrutia M, Silva JM. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA-A 21-1 and NMP 22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001 165 : 1462 7
17. Malik S, Murphy WM. Monitoring patients for bladder neoplasms what can be expected of urinary cytology consultations in daily practice? Urology 1999 54 : 62 6
18. Sack MJ, Artymyshyn RL, Tomaszewski JE. Diagnostic value of bladder wash cytology with special reference to low grade urothelial neoplasms. Acta Cytol 1995 39 : 187 94
19. Coughlin SS, Trock B, Criqui MH, Pickle LW, Browner D, Tefft MC. The logistic modeling of sensitivity, specificity, and predictive value of a diagnostic test. J Clin Epidemiol 1992 45 : 1 7
20. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003 21 : 1315 30
21. Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005 293 : 810 6
22. Pfister C, Chautard D, Devonec M et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003 169 : 921 4
23. Brown FM. Urine cytology. Is it still the gold standard for screening? Urol Clin North Am 2000 27 : 25 37
24. Sherman AB, Koss LG, Adams SE. Interobserver and intraobserver differences in the diagnosis of urothelial cells. Anal Quant Cytol 1984 6 : 112 20
25. Van der Poel HG, Van Balken MR, Schamhart DH et al. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology 1998 51 : 44 50
26. Sarosdy MF, Hudson MA, Ellis WJ et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 1997 50 : 349 53
27. Raitanen MP, Marttila T, Nurmi M et al. Human complement factor H-related protein test for monitoring bladder cancer. J Urol 2001 165 : 374 7
28. Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002 168 : 1950 4
29. Laudadio J, Keane TE, Reeves HM et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int 2005 96 : 1280 5
30. Skacel M, Fahmy M, Brainard JA et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003 169 : 2101 5